Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen to Cut Costs of Instrumentation Division; Expects Drop in Q2 Revenues

NEW YORK, July 1 (GenomeWeb News) - Ciphergen Biosystems expects a significant drop in revenues for the second quarter and plans to cut costs in its instrumentation division, the company said yesterday.

 

Ciphergen estimates revenues of $10-11 million for the quarter ending yesterday, down from $14.3 million during the same period last year.

 

Bill Rich, the company's president and CEO, said in statement that "we will take steps to reduce operating expenses in our Biosystems Division more in line with a reduced revenue run rate." He also told GenomeWeb News that it is unclear yet whether the cost cutting will involve layoffs. More details will be announced during a webcast later this month.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.